RASSURE - Virtual Reality to Soothe, Secure, Simulate Uses, and Successfully Complete the Examination (RASSURE)
Pilot Study Evaluating the Impact of Immersive Virtual Reality-Based Habituation to Medical Care Compared With Traditional Habituation to Medical Care on Anxiety Levels in People With Disabilities Receiving Care in a Dedicated Disability Consultation Setting
The RASSURE study aims to evaluate the effect of a preparation for care programme combining a traditional habituation method with a digital immersive virtual reality tool ('PREPASOINS_VR'), compared with traditional habituation alone. In particular, the study aims to measure the impact of the use of IVR on the anxiety experienced during the actual treatment, as well as on various indicators relating to the delivery of the treatment, its progress and the experience of the patients.
Visão geral do estudo
Status
Status
Condições
Condições
Intervenção / Tratamento
Intervenção / Tratamento
Tipo de estudo
Tipo de estudo
Inscrição (Estimado)
Inscrição
Estágio
Estágio
- Não aplicável
Contactos e Locais
Contato de estudo
Contato de estudo
- Nome: Aurélie Dr DURUFLE, Principal Investigator
- Número de telefone: +33299295099
- E-mail: aurelie.durufle@fondationsainthelier.com
Locais de estudo
-
-
-
Rennes, França
- Fondation Saint-Hélier
-
Contato:
- Aurélie DURUFLE
- Número de telefone: +33299295099
- E-mail: aurelie.durufle@fondationsainthelier.com
-
Thorigné-Fouillard, França
- MAS le Placis Vert - DAPAH - CHGR
-
Contato:
- CELINE BUCHAILLET
- Número de telefone: 0223271133
- E-mail: c.buchaillet@ch-guillaumeregnier.fr
-
-
Critérios de participação
Critérios de elegibilidade
Critérios de elegibilidade
Idades elegíveis para estudo
Aceita Voluntários Saudáveis
Gêneros Elegíveis para o Estudo
Descrição
Inclusion Criteria:
-
Adults:
- Adults (age ≥ 18) at the time of enrollment
- Users of the Handi Accès 35 program who have experienced treatment failure in mainstream healthcare settings
- Individuals with a psychological or mental disability (e.g., autism spectrum disorders, Pervasive Developmental Disorder (PDD), Down syndrome, cerebral palsy, etc.) that creates significant barriers to accessing care (e.g., failure to receive care, failure due to past experience (perceived/contact-related), refusal of care, architectural barriers, anticipated failure, lack of external care options) documented in the medical record
- Requiring a period of adjustment to care
- Having given free and informed consent
- Able to understand the French language (care acclimatization kits-available only in French)
- Enrolled in a social security program or eligible for an equivalent benefit
Minors:
- Children aged between 9 and 17 (inclusive) at the time of inclusion
- Users of the Handi Accès 35 scheme who have been unable to access care in mainstream settings
- People with a psychological or mental disability (for example: autism spectrum disorders, Pervasive Developmental Disorder (PDD), Down's syndrome, cerebral palsy, etc.) which creates significant barriers to accessing care (e.g. failure to access care, failure due to experience (perception/interaction), refusal of treatment, architectural barriers, anticipated failure, no external care provision) documented in the medical record
- Requiring a period of adjustment to care
- Registered with a social security scheme or entitled to an equivalent benefit
- Able to understand French (care familiarisation kits - available in French only)
- Minors for whom free, informed and written consent has been obtained from both holders of parental authority or, in exceptional cases, from a single holder under the conditions set out in Article L1122-2 of the Public Health Code.
Caregivers:
- Adult: a person aged 18 or over
- Informed consent: voluntary agreement to participate in the study following a full explanation of its terms.
- Registered with a social security scheme or an eligible dependant
- Agree to and be able to carry out the treatment familiarisation process with their relative and to accompany them to the dedicated consultation
Exclusion Criteria:
-
majors : Participants requiring urgent medical care that prevents them from completing an 8-week familiarisation period with the treatment
- Participants at high risk of epileptic seizures, or with uncontrolled epilepsy in the investigator's judgement, which contraindicates the use of VR.
- Individuals with visual impairments that make the use of VR impossible
- Individuals who refuse to wear the VR headset, in the investigator's judgement
- Pregnant or breastfeeding women
- Individuals deprived of their liberty by a judicial decision (excluding guardianship or curatorship) or an administrative decision.
- Individuals in an emergency situation who are unable to give their prior consent.
minors : Individuals requiring urgent care that prevents them from completing an 8-week acclimatisation period
- Refusal expressed by the child, notwithstanding the prior consent of the parents or holders of parental authority
- Children subject to a court-ordered protection measure involving a specific placement, which is incompatible with participation in the study
- A person presenting a major risk of epileptic seizures, or uncontrolled epilepsy in the investigator's judgement, which contraindicates the use of VR.
- A person with visual impairments that make the use of VR impossible
- A person refusing to wear the VR headset, in the investigator's judgement
- Individuals deprived of their liberty by a judicial decision (excluding guardianship or curatorship) or an administrative decision.
- Individuals in an emergency situation who are unable to give their prior consent.
Caregiver: Vulnerable individuals referred to in Articles L. 1121-5 to 8 and L. 1122-1-2 of the Public Health Code are excluded from the study:
- Pregnant women, women in labour or breastfeeding women
- Persons deprived of their liberty by a judicial decision (including guardianship, curatorship and judicial protection) or an administrative decision
- Persons receiving psychiatric care or admitted to a health or social care facility for purposes other than research
- Persons in an emergency situation who are unable to give their prior consent
Plano de estudo
Como o estudo é projetado?
Detalhes do projeto
- Finalidade Principal: Pesquisa de serviços de saúde
- Alocação: Randomizado
- Modelo Intervencional: Atribuição Paralela
- Mascaramento: Nenhum (rótulo aberto)
Número de braços
Armas e Intervenções
Grupo de Participantes / BraçoGrupo de Participantes / Braço |
Intervenção / TratamentoIntervenção / Tratamento |
|---|---|
|
Comparador Ativo: Traditional treatment habituation method only
For each group, once they have been briefed, the following materials will be provided:
|
A traditional care habituation programme designed to familiarise participants with upcoming medical and care procedures. The programme uses conventional preparation materials and information to help participants understand and anticipate the different stages of the procedures. It aims to reduce anxiety associated with medical and care procedures. This intervention is provided to participants in both the control and experimental groups. In the experimental group, it is supplemented by an immersive virtual reality familiarisation programme (PREPASOINS_VR). The Embrace Plus wristband is worn by participants in both study groups to monitor anxiety levels during the study. It is used as a monitoring device and does not deliver any therapeutic intervention. A non-electronic dummy wristband used during the treatment habituation sessions to familiarise participants with wearing a wristband before the actual treatment procedure. The dummy wristband is used for habituation purposes only and does not record or monitor physiological parameters. |
|
Experimental: Traditional care habituation combined with virtual reality
In addition to the traditional care habituation materials provided to participants in the control group, participants in this group will also receive:
The virtual reality programme includes eight care scenarios covering dental care, dental mobile unit visits, gynaecological and ophthalmological consultations, follow-up appointments for physical medicine and rehabilitation, somatic assessments, blood tests and electrocardiograms. |
A traditional care habituation programme designed to familiarise participants with upcoming medical and care procedures. The programme uses conventional preparation materials and information to help participants understand and anticipate the different stages of the procedures. It aims to reduce anxiety associated with medical and care procedures. This intervention is provided to participants in both the control and experimental groups. In the experimental group, it is supplemented by an immersive virtual reality familiarisation programme (PREPASOINS_VR). The Embrace Plus wristband is worn by participants in both study groups to monitor anxiety levels during the study. It is used as a monitoring device and does not deliver any therapeutic intervention. A non-electronic dummy wristband used during the treatment habituation sessions to familiarise participants with wearing a wristband before the actual treatment procedure. The dummy wristband is used for habituation purposes only and does not record or monitor physiological parameters. An immersive virtual reality headset used with the PREPASOINS_VR solution. The device enables participants to view immersive 360-degree videos presenting different medical and care scenarios as part of the care familiarisation programme. It is used exclusively in the experimental group. |
O que o estudo está medindo?
Medidas de resultados primários
Medidas de resultados primários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Skin Conductance (SC) During the Actual Treatment Procedure (µS)
Prazo: At Visit 1, during the actual treatment procedure (2-3 months after enrolment).
|
Skin conductance (SC), expressed in microsiemens (µS), measured using an Empatica wristband during the actual treatment procedure at Visit 1. Skin conductance reflects changes in the electrical conductance of the skin associated with sweat secretion by the eccrine sweat glands, particularly those located on the palms and soles. Skin conductance is a physiological measure of electrodermal activity (EDA) associated with sympathetic nervous system activity. |
At Visit 1, during the actual treatment procedure (2-3 months after enrolment).
|
Medidas de resultados secundários
Medidas de resultados secundários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Change From Baseline in Caregiver-Reported Patient Anxiety Score on the Visual Analogue Scale at 2-3 Months
Prazo: At baseline (inclusion) and at Visit 1 (2-3 months after enrolment).
|
Patient anxiety score as perceived and reported by the caregiver, measured using a Visual Analogue Scale (VAS) ranging from 0 to 10, where 0 indicates no anxiety and 10 indicates maximum anxiety. The assessment is performed at inclusion (baseline) and at Visit 1 (2-3 months after enrolment). The change in anxiety score between baseline and Visit 1 will be reported. Higher scores indicate higher levels of perceived anxiety (worse outcome). |
At baseline (inclusion) and at Visit 1 (2-3 months after enrolment).
|
|
Percentage of Care Provided During the Actual Treatment Procedure (%)
Prazo: Visit 1, during the actual treatment procedure (2-3 months after enrolment).
|
The degree of care provision during the actual treatment procedure, assessed by the healthcare professional using a numerical scale ranging from 0% (care not provided) to 100% (care fully provided). Intermediate values indicate partial care provision. A derived categorical variable will also be reported, distinguishing complete care provision (100%) from incomplete care provision (partial care provision or no care provided). |
Visit 1, during the actual treatment procedure (2-3 months after enrolment).
|
|
Use of Premedication Before the Treatment Procedure (Yes/No)
Prazo: At Visit 1 (between 2 and 3 months after enrolment).
|
Use of premedication before the actual treatment procedure, recorded as a binary variable (yes/no). When premedication is used, its type (pharmacological or non-pharmacological) will also be recorded. For pharmacological premedication, the medication name and dose will be documented, when applicable. |
At Visit 1 (between 2 and 3 months after enrolment).
|
|
Use and Acceptance of Conscious Sedation With Nitrous Oxide/Oxygen (MEOPA)
Prazo: During the actual treatment procedure at Visit 1 (2-3 months after enrolment).
|
Use of conscious sedation with nitrous oxide/oxygen (MEOPA) during the actual treatment procedure, recorded as a categorical variable: administered and accepted, refused, or not used. |
During the actual treatment procedure at Visit 1 (2-3 months after enrolment).
|
|
Duration of Conscious Sedation With Nitrous Oxide/Oxygen (MEOPA) (Minutes)
Prazo: During the actual treatment procedure at Visit 1 (2-3 months after enrolment).
|
Duration of MEOPA administration during the actual treatment procedure, measured in minutes among participants who receive conscious sedation. |
During the actual treatment procedure at Visit 1 (2-3 months after enrolment).
|
|
Number of Preparatory Visits Before the Actual Treatment Procedure
Prazo: From enrolment until the actual treatment procedure at Visit 1 (2-3 months after enrolment).
|
Number of preparatory visits ("dry runs") completed before the actual treatment procedure. A preparatory visit is defined as a visit during which the patient attends the treatment setting but the planned treatment is not performed. The total number of preparatory visits completed before the actual treatment will be recorded. |
From enrolment until the actual treatment procedure at Visit 1 (2-3 months after enrolment).
|
|
Pain Score During the Treatment Procedure Measured Using the Postoperative Pain Assessment Grid for Individuals with Intellectual Disabilities (GED-DI)
Prazo: Immediately after the actual treatment procedure at Visit 1 (2-3 months after enrolment)
|
Pain experienced by the patient during the treatment procedure, measured using the Postoperative Version of the Pain Assessment Grid for Individuals with Intellectual Disabilities (Grille d'Évaluation de la Douleur - Déficience Intellectuelle, GED-DI). The scale consists of 27 behavioral items, each scored from 0 to 3, resulting in a total score ranging from 0 to 81. The scale is completed after the treatment by the healthcare professional who performed the procedure, with the assistance of a companion when necessary. Higher scores indicate greater pain intensity (worse outcome). Scores of 6-10 indicate mild pain, while scores of 11 or higher indicate moderate to severe pain. |
Immediately after the actual treatment procedure at Visit 1 (2-3 months after enrolment)
|
|
Caregiver Satisfaction With the Care Provided During the Treatment Procedure
Prazo: Immediately after the actual treatment procedure at Visit 1 (2-3 months after enrolment).
|
Caregiver satisfaction with the care provided during the actual treatment procedure, assessed using a 5-point Likert scale ranging from 1 (very dissatisfied) to 5 (very satisfied). The minimum score is 1 and the maximum score is 5. Higher scores indicate greater satisfaction and a better outcome. The questionnaire is completed by the caregiver, if present during the consultation. |
Immediately after the actual treatment procedure at Visit 1 (2-3 months after enrolment).
|
|
Healthcare Professional-Rated Ease of Performing the Treatment Procedure
Prazo: Immediately after the actual treatment procedure at Visit 1 (2-3 months after enrolment).
|
The perceived ease of performing the actual treatment procedure, assessed by the healthcare professional using a 5-point Likert scale ranging from 1 (very difficult) to 5 (very easy). The minimum score is 1 and the maximum score is 5. Higher scores indicate greater ease of performing the procedure and a better outcome. |
Immediately after the actual treatment procedure at Visit 1 (2-3 months after enrolment).
|
|
Duration of the Treatment Habituation Period (Days)
Prazo: From the first habituation session until the actual treatment procedure at Visit 1 (2-3 months after enrolment).
|
Duration of the treatment habituation period, measured in days from the date of the first habituation session to the date of the actual treatment procedure. The duration is calculated as the number of calendar days between these two dates. |
From the first habituation session until the actual treatment procedure at Visit 1 (2-3 months after enrolment).
|
|
Number of Treatment Habituation Sessions
Prazo: From enrolment until the actual treatment procedure at Visit 1 (2-3 months after enrolment).
|
Total number of habituation sessions completed by each participant between enrolment and the actual treatment procedure. |
From enrolment until the actual treatment procedure at Visit 1 (2-3 months after enrolment).
|
|
Recruitment Rate (%)
Prazo: From the start of recruitment until the end of the recruitment period, up to 12 months
|
Proportion of eligible participants who agreed to participate and were enrolled in the study, calculated as the number of enrolled participants divided by the number of eligible participants approached, multiplied by 100. |
From the start of recruitment until the end of the recruitment period, up to 12 months
|
|
Recruitment Speed (Participants per Month)
Prazo: Up to 12 months
|
Average number of participants enrolled per month during the recruitment period, calculated as the total number of enrolled participants divided by the number of months of active recruitment. |
Up to 12 months
|
|
Eligibility Rate (%)
Prazo: Up to 12 months
|
Proportion of individuals assessed for eligibility who met all study eligibility criteria, calculated as the number of eligible individuals divided by the total number of individuals assessed for eligibility, multiplied by 100. |
Up to 12 months
|
|
participant Refusal Rate (%)
Prazo: Up to 12 months
|
Proportion of individuals approached for study participation who declined to participate, calculated as the number of individuals who refused participation divided by the total number of individuals approached, multiplied by 100. |
Up to 12 months
|
|
Intervention Adherence Rate (%)
Prazo: From enrolment up to Visit 1, up to 3 months
|
Proportion of enrolled participants who completed at least two treatment habituation sessions, calculated as the number of participants completing at least two sessions divided by the total number of enrolled participants, multiplied by 100. |
From enrolment up to Visit 1, up to 3 months
|
|
Acceptance Rate of the Dummy Wristband (%)
Prazo: During the habituation period prior to Visit 1, up to 3 months post-enrolment
|
Proportion of participants who accepted wearing the dummy wristband, calculated as the number of participants who accepted wearing the dummy wristband divided by the total number of participants offered the dummy wristband, multiplied by 100. |
During the habituation period prior to Visit 1, up to 3 months post-enrolment
|
|
Acceptance Rate of the Embrace Plus Wristband on the Treatment Day (%)
Prazo: At Visit 1, up to 3 months post-enrolment
|
Proportion of participants who accepted wearing the Embrace Plus wristband during the actual treatment procedure, calculated as the number of participants who accepted wearing the wristband divided by the total number of participants offered the wristband, multiplied by 100. |
At Visit 1, up to 3 months post-enrolment
|
|
Main Reasons for Non-Participation
Prazo: Up to 12 months
|
Main reasons reported by individuals who declined participation in the study, recorded as categorical data. |
Up to 12 months
|
|
Time Interval Between Initial Contact and Study Inclusion (Days)
Prazo: From initial contact until study inclusion, up to 12 months
|
Time interval, measured in calendar days, between the date of initial contact with the potential participant and the date of study inclusion. |
From initial contact until study inclusion, up to 12 months
|
|
Participant Follow-up Completion Rate (%)
Prazo: From enrolment until Visit 1 (2-3 months after enrolment).
|
Proportion of enrolled participants who completed the planned study follow-up assessment at Visit 1, calculated as the number of participants completing Visit 1 divided by the total number of enrolled participants, multiplied by 100 |
From enrolment until Visit 1 (2-3 months after enrolment).
|
Colaboradores e Investigadores
Patrocinador
Patrocinador
Datas de registro do estudo
Datas Principais do Estudo
Início do estudo (Estimado)
Início do estudo
Conclusão Primária (Estimado)
Conclusão Primária
Conclusão do estudo (Estimado)
Conclusão do estudo
Datas de inscrição no estudo
Enviado pela primeira vez
Enviado pela primeira vez
Enviado pela primeira vez que atendeu aos critérios de CQ
Enviado pela primeira vez que atendeu aos critérios de CQ
Primeira postagem (Real)
Primeira postagem
Atualizações de registro de estudo
Última Atualização Postada (Real)
Última Atualização Postada
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última verificação
Última verificação
Mais Informações
Termos relacionados a este estudo
Outros números de identificação do estudo
Outros números de identificação do estudo
- 2026-A01473-48
Informações sobre medicamentos e dispositivos, documentos de estudo
Estuda um medicamento regulamentado pela FDA dos EUA
Estuda um produto de dispositivo regulamentado pela FDA dos EUA
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .